UQ spinout Intracellica Bio received more than $1.6 million to develop antibodies that enter neurons and attack toxic Tau. The project is testing the UQ-developed RNJ1 Tau antibody as a possible treatment for Alzheimer's disease and related conditions.
Tau is a brain protein that helps hold neurons in shape. In Alzheimer's, faulty Tau forms tangles that block normal cell work. This funding supports engineering work to reach that internal Tau.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the funding is building
- Why Tau inside neurons matters
- How the cell-entry design works
- What families should do now
What the funding is building
The Queensland Brain Institute reports new funding to engineer antibodies that enter neurons through CUREator+ Dementia and Cognitive Decline. The award supports Intracellica Bio, a UQ spinout focused on neuron-penetrating antibodies.
UQ News reports work to advance RNJ1 toward dementia therapy for Alzheimer's and other neurodegenerative conditions. The project is led by Prof. Jürgen Götz and Dr Esteban Cruz Gonzalez, with drug development support from UQ's National Biologics Facility.
Why Tau inside neurons matters
Healthy Tau supports structure and transport inside neurons. In Alzheimer's, abnormal Tau clumps into tangles that disrupt cell function.
That damage affects memory, thinking, and daily function in dementia. Earlier QBI laboratory work found RNJ1 helped restore protein balance disturbed by Tau tangles.
How the cell-entry design works
Most antibodies stay outside cells, while disease-causing Tau sits inside neurons. Researchers are fusing Tau antibodies to proteins designed to cross the neuronal membrane.
The goal is to carry the antibody across that membrane to reach internal Tau. Existing focused-ultrasound methods help antibodies first cross the blood-brain barrier, while cell entry is the next hurdle.
What families should do now
This is laboratory and commercialisation work, not an available treatment. UQ News notes there are no approved antibody therapies targeting Tau, so RNJ1 remains investigational. Families concerned about memory change can take practical steps now:.
- Track symptoms, medications, sleep, and daily function for medical visits.
- Ask a GP or memory clinic about assessment, care planning, and support services.
- Follow university announcements for future research updates rather than seeking this antibody clinically.
You Might Also Like
- Safety Questions After the 2026 LiBBY Dementia Trial: Questions Family Caregivers Can Ask About the Research
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Questions Family Caregivers Can Ask About the Research
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Questions Family Caregivers Can Ask About the Research
